SCHEMBL15575294

SCHEMBL15575294

CON(C)C(=O)c1cnc(Br)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.43
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
ICAM1 P05362 1/20 0.39
SELE P16581 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
HCAR2 Q8TDS4 1/20 0.34
HSD17B1 P14061 2/20 0.33
HSD17B2 P37059 2/20 0.33
MLYCD O95822 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
ALDH1A1 P00352 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22021995 0.83 HCAR2 (0.55) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL960053 0.82 LMNA (0.44) ICAM1SELEKMT2AHCAR2HSD17B1
SCHEMBL10183970 0.81 CLK1 (0.42) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL20487461 0.78 CLK1 (0.40) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL19764489 0.78 CLK1 (0.40) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL23039876 0.76 CLK1 (0.39) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL16332917 0.76 HTR2C (0.40) KMT2AHDAC3HDAC4HDAC6ALDH1A1
SCHEMBL17747762 0.75 FAAH (0.40) CLK1DYRK1ADYRK1BICAM1SELE
SCHEMBL2073998 0.75 NPC1 (0.58) TRPM8MEN1KMT2AHSD17B1HSD17B2
SCHEMBL472995 0.74 CSNK2A2 (0.42) HCAR2ALDH1A1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023211854-A1 KCNT1 INHIBITORS COMPRISING A THIAZOLE CORE AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. (US) 2023-11-02 WO disclosed
CN-116669744-A Nrf2 activating compounds 千寿制药株式会社 2023-08-29 CN disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
CN-114080389-A Nrf2 activating compound 千寿制药株式会社 2022-02-22 CN disclosed
WO-2021002473-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2021-01-07 WO disclosed
WO-2014035872-A1 TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN AMGEN INC. (US) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 CLK1 2602/4885DYRK1A 3130/4885DYRK1B 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.